LRRK2
Top inhibitors
| Drug | Inhibition % | Gini |
|---|---|---|
| Ceritinib | 99.4 | 0.62 |
| Gilteritinib | 97.2 | 0.51 |
| Brigatinib | 96.6 | 0.51 |
| Sunitinib | 95.8 | 0.52 |
| Defactinib | 95.8 | 0.45 |
| Alectinib | 94.5 | 0.65 |
| Midostaurin | 93.0 | 0.50 |
| Axitinib | 92.3 | 0.69 |
| Pacritinib | 83.4 | 0.45 |
| Osimertinib | 82.4 | 0.73 |
| Abemaciclib | 79.1 | 0.56 |
| Upadacitinib | 73.3 | 0.66 |
| Bosutinib | 69.5 | 0.55 |
| Fostamatinib | 69.3 | 0.61 |
| Repotrectinib | 68.8 | 0.61 |
Known variants
Cancer associations
| Mutation | Cancer type | Organ | Source |
|---|---|---|---|
G2019S | carcinoma_large_intestine | Large Intestine | https://doi.org/10.1093/nar/gkaa945 |
R1441C | carcinoma_endometrium | Uterus | https://doi.org/10.1093/nar/gkaa945 |
R1441C | UCEC-US | Uterus | https://doi.org/10.1093/nar/gkaa945 |
R1441C | UCEC | Uterus | https://doi.org/10.1093/nar/gkaa945 |
I2020T | carcinoma_breast | Breast | https://doi.org/10.1158/2159-8290.CD-12-0094 |
I2020T | AML-US | Blood/Lymphatic System | https://doi.org/10.1158/2159-8290.CD-12-0095 |
I2020T | UCEC | Uterus | https://doi.org/10.1158/2159-8290.CD-12-0096 |